JONATHAN PEARCE JOINS DKMS AS NEW CEO

13 June 2019

We are pleased to announce Jonathan Pearce as our new UK Chief Executive Officer of UK operations. 

Jonathan has over 15 years’ CEO experience in the UK charity sector and has led organisations such as Adoption UK and, more recently, Lymphoma Action from 2013 to 2018.

Wealth of knowledge

Jonathan brings with him a vast knowledge of blood cancer and blood disorders. Prior to joining DKMS, he worked for the global Lymphoma Coalition Europe, where he was Regional Director.

Jonathan will play an important role in helping us to spearhead our growth within the UK market. 

Stephan Schumacher, Trustee of DKMS in the UK, said: “We are delighted to welcome Jonathan to lead our UK operations.

Jonathan has a wealth of knowledge and experience within the charity and health sectors, which will be invaluable to us as an organisation.

“This is an exciting time for DKMS in the UK and we look forward to growing our presence and providing more people with second chances at life under his leadership.”

A bright future ahead

Jonathan joins DKMS at an important time in our history.

It is six years since we’ve been in the UK, and earlier this year we achieved an important milestone of recruiting our 500k active registered blood stem cell donor and we’ve given over 800 people a second chance at life.

Jonathan said: “I am thrilled to join the DKMS team at such an exciting time in the organisation’s history.

Together with my UK and international colleagues, and the vital support of our patients, donors, supporters and partners, I look forward to extending the impact our work in the UK and taking the organisation further towards our vision of providing a matching blood stem cell donor for everyone who needs one.”

How you can help?

Are you inspired to help register potential lifesavers aged between 17-55?

If this is something that might be of interest to you then you might want to consider working for us or becoming a DKMS volunteer to help us continue the fight against blood cancer and blood disorders.